Gene,uniprot_id,Orig_AA,Position,Mutated_AA,X6
BRAF,P15056,M,53,D,"/note=""M->D: Reduces interaction with KSR1 and MAP2K1 and thus phosphorylation of MAP2K1."" /evidence=""ECO:0000269|PubMed:29433126"""
BRAF,P15056,K,88,E,"/note=""K->E: Reduces interaction with KSR1 and MAP2K1 and thus phosphorylation of MAP2K1."" /evidence=""ECO:0000269|PubMed:29433126"""
BRAF,P15056,K,483,S,"/note=""K->S: Reduces kinase activity with MAP2K1."" /evidence=""ECO:0000269|PubMed:21441910"""
EGFR,P00533,Y,275,A,"/note=""Y->A: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A- 309."" /evidence=""ECO:0000269|PubMed:12297050"""
EGFR,P00533,F,287,A,"/note=""F->A: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A- 309."" /evidence=""ECO:0000269|PubMed:12297050"""
EGFR,P00533,R,309,S,"/note=""R->S: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A- 275. Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-287."" /evidence=""ECO:0000269|PubMed:12297050"""
EGFR,P00533,L,688,A,"/note=""L->A: Strongly reduced phosphorylation."" /evidence=""ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:19563760"""
EGFR,P00533,V,689,A,"/note=""V->A: Reduced autophosphorylation."" /evidence=""ECO:0000269|PubMed:19560417"""
EGFR,P00533,E,690,A,"/note=""E->A: Reduced phosphorylation."" /evidence=""ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:19563760"""
EGFR,P00533,L,692,A,"/note=""L->A,P: Strongly reduced phosphorylation."" /evidence=""ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:19563760"""
EGFR,P00533,T,693,D,"/note=""T->D: Strongly reduced phosphorylation."" /evidence=""ECO:0000269|PubMed:19560417"""
EGFR,P00533,P,694,A,"/note=""P->A: Strongly reduced phosphorylation."" /evidence=""ECO:0000269|PubMed:19560417"""
EGFR,P00533,P,699,A,"/note=""P->A: Reduced phosphorylation."" /evidence=""ECO:0000269|PubMed:19560417"""
EGFR,P00533,D,974,A,"/note=""D->A: Strongly reduced phosphorylation."""
EGFR,P00533,R,977,A,"/note=""R->A: Reduced phosphorylation."" /evidence=""ECO:0000269|PubMed:19563760"""
ERBB2,P04626,L,317,A,"/note=""LH->AA: Reduces dimerization with ERBB3."" /evidence=""ECO:0000269|PubMed:15093539"""
ERBB2,P04626,H,318,A,"/note=""LH->AA: Reduces dimerization with ERBB3."" /evidence=""ECO:0000269|PubMed:15093539"""
FGFR1,P11362,Y,99,C,"/note=""Y -> C (in HH2; impairs the tertiary folding resulting in incomplete glycosylation and reduced cell surface expression; dbSNP:rs727505373)"" /evidence=""ECO:0000269|PubMed:12627230, ECO:0000269|PubMed:19820032"" /id=""VAR_017886"""
FGFR1,P11362,Y,228,D,"/note=""Y -> D (in HH2; some patients also carry KISS1R mutations; impairs the tertiary folding resulting in incomplete glycosylation and reduced cell surface expression)"" /evidence=""ECO:0000269|PubMed:19820032, ECO:0000269|PubMed:23643382"" /id=""VAR_069289"""
FGFR1,P11362,I,239,T,"/note=""I -> T (in HH2; some patients also carry PROKR2 and GNRH1 mutations; impairs the tertiary folding resulting in incomplete glycosylation and reduced cell surface expression)"" /evidence=""ECO:0000269|PubMed:19820032, ECO:0000269|PubMed:23643382"" /id=""VAR_069290"""
FGFR1,P11362,R,250,Q,"/note=""R -> Q (in HH2; with or without anosmia; results in Kallmann syndrome in the presence of HS6ST1 mutation TRP- 306; reduces receptor affinity for fibroblast growth factor; dbSNP:rs121909645)"" /evidence=""ECO:0000269|PubMed:19820032, ECO:0000269|PubMed:21700882, ECO:0000269|PubMed:23643382, ECO:0000269|PubMed:25077900"" /id=""VAR_069291"""
FGFR1,P11362,P,722,H,"/note=""P -> H (in HH2; associated with K-724; also found in a family member with isolated anosmia; reduced tyrosine kinase activity; dbSNP:rs267606805)"" /evidence=""ECO:0000269|PubMed:16606836, ECO:0000269|PubMed:23643382"" /id=""VAR_031005"""
FGFR1,P11362,N,724,K,"/note=""N -> K (in HH2; associated with H-722; also found in a family member with isolated anosmia; reduced tyrosine kinase activity; dbSNP:rs267606806)"" /evidence=""ECO:0000269|PubMed:16606836, ECO:0000269|PubMed:23643382"" /id=""VAR_031007"""
FGFR1,P11362,R,577,E,"/note=""R->E: Strongly reduced autophosphorylation in response to FGF signaling. No effect on in vitro kinase activity."" /evidence=""ECO:0000269|PubMed:20133753"""
FGFR1,P11362,Y,654,F,"/note=""Y->F: Reduced kinase activity. Loss of autophosphorylation and kinase activity; when associated with F-653."" /evidence=""ECO:0000269|PubMed:8622701"""
FGFR2,P21802,M,391,R,"/note=""M -> R (in BBDS; the mutation selectively reduces plasma-membrane levels of the protein and markedly diminishes the receptor's responsiveness to extracellular FGF; dbSNP:rs387906677)"" /evidence=""ECO:0000269|PubMed:22387015"" /id=""VAR_067978"""
FGFR2,P21802,A,628,T,"/note=""A -> T (in LADDS; strongly reduced kinase activity; dbSNP:rs121918509)"" /evidence=""ECO:0000269|PubMed:16501574"" /id=""VAR_029884"""
FGFR2,P21802,N,265,Q,"/note=""N->Q: Reduced N-glycosylation. Reduced expression at the cell surface."" /evidence=""ECO:0000269|PubMed:16844695"""
FLT3,P36888,Y,589,F,"/note=""Y->F: Reduced phosphorylation of the wild-type kinase in response to ligand binding. No effect on the phosphorylation of the constitutively activated mutant kinase variants. Abolishes activation of STAT5A."" /evidence=""ECO:0000269|PubMed:16627759, ECO:0000269|PubMed:16684964, ECO:0000269|PubMed:9737679"""
KIT,P10721,R,381,A,"/note=""R->A: Reduces autophosphorylation in response to KITLG/SCF."" /evidence=""ECO:0000269|PubMed:17662946"""
KIT,P10721,E,386,A,"/note=""E->A: Reduces autophosphorylation in response to KITLG/SCF."" /evidence=""ECO:0000269|PubMed:17662946"""
MAP2K1,Q02750,K,97,A,"/note=""K->A: Loss of catalytic activity. Strongly reduces phosphorylation upon UV irradiation."" /evidence=""ECO:0000269|PubMed:20956560"""
PDGFRA,P16234,Y,720,F,"/note=""Y->F: Strongly reduced interaction with PTPN11 and GRB2."" /evidence=""ECO:0000269|PubMed:8943348"""
NA,P35968,C,482,R,"/note=""C -> R (in HCI; associated with disease susceptibility; expression of FLT1 in hemangioma endothelial cells is markedly reduced and KDR activity is increased compared to controls; low FLT1 expression in hemangioma cells is caused by reduced activity of a pathway involving ITGB1, ANTXR1, KDR and NFATC2IP; the mutation predicts to result in loss-of-function and disruption of the normal association of these molecules; dbSNP:rs34231037)"" /evidence=""ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:18931684"" /id=""VAR_042057"""
KDR,P35968,V,848,E,"/note=""V -> E (strongly reduced autophosphorylation and kinase activity; dbSNP:rs1139776)"" /evidence=""ECO:0000269|PubMed:10037737, ECO:0000269|PubMed:1656371"" /id=""VAR_046679"""
KDR,P35968,R,726,A,"/note=""R->A: Strongly reduced autophosphorylation and activation of MAP kinases."" /evidence=""ECO:0000269|PubMed:20080685"""
KDR,P35968,D,731,A,"/note=""D->A: Strongly reduced autophosphorylation and activation of MAP kinases."" /evidence=""ECO:0000269|PubMed:20080685"""
KDR,P35968,Y,996,F,"/note=""Y->F: Strongly reduced autophosphorylation. Reduces phosphorylation of PLCG1."" /evidence=""ECO:0000269|PubMed:10102632"""
KDR,P35968,Y,1054,F,"/note=""Y->F: Strongly reduced autophosphorylation. Abolishes phosphorylation of downstream signaling proteins; when associated with F-1059."" /evidence=""ECO:0000269|PubMed:10102632"""
KDR,P35968,Y,1059,F,"/note=""Y->F: Strongly reduced autophosphorylation. Abolishes phosphorylation of downstream signaling proteins; when associated with F-1054."" /evidence=""ECO:0000269|PubMed:10102632"""
